FY2026 EPS Forecast for Opus Genetics Reduced by Analyst

Opus Genetics, Inc. (NASDAQ:IRD) – Analysts at Brookline Capital Markets decreased their FY2026 earnings estimates for Opus Genetics in a research note issued to investors on Wednesday, June 10th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn ($1.31) per share for the year, down from their previous estimate of ($0.57). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.97) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ Q4 2026 earnings at ($0.06) EPS and FY2027 earnings at ($0.77) EPS.

Several other research analysts have also recently weighed in on the stock. Citigroup started coverage on shares of Opus Genetics in a report on Tuesday, April 28th. They issued an “outperform” rating for the company. BTIG Research boosted their price objective on shares of Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Guggenheim initiated coverage on shares of Opus Genetics in a research report on Thursday, June 4th. They issued a “buy” rating and a $16.00 price objective on the stock. Leerink Partners initiated coverage on shares of Opus Genetics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Chardan Capital boosted their price objective on shares of Opus Genetics from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Opus Genetics Stock Up 0.5%

Opus Genetics stock opened at $3.91 on Friday. The stock has a market capitalization of $322.85 million, a PE ratio of -2.94 and a beta of 0.56. Opus Genetics has a twelve month low of $0.90 and a twelve month high of $5.81. The company has a 50 day moving average of $4.80 and a 200-day moving average of $3.65.

Opus Genetics (NASDAQ:IRD) last issued its earnings results on Tuesday, May 12th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.59). The firm had revenue of $2.16 million during the quarter, compared to the consensus estimate of $2.93 million. Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 338.88%.

Insider Activity

In other Opus Genetics news, CEO George Magrath sold 9,511 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.22, for a total transaction of $49,647.42. Following the sale, the chief executive officer directly owned 1,741,344 shares of the company’s stock, valued at approximately $9,089,815.68. This represents a 0.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 7,842 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total transaction of $40,621.56. Following the sale, the chief financial officer directly owned 592,158 shares in the company, valued at $3,067,378.44. This trade represents a 1.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 1,773,395 shares of company stock valued at $7,777,278. 11.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Opus Genetics

Large investors have recently modified their holdings of the stock. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics in the fourth quarter valued at about $25,000. Virtu Financial LLC bought a new position in shares of Opus Genetics in the fourth quarter valued at about $34,000. Johnson Investment Counsel Inc. bought a new position in shares of Opus Genetics in the fourth quarter valued at about $40,000. Raymond James Financial Inc. raised its position in shares of Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after purchasing an additional 11,000 shares during the period. Finally, Blair William & Co. IL raised its position in shares of Opus Genetics by 12.3% in the fourth quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock valued at $55,000 after purchasing an additional 3,000 shares during the period. 14.97% of the stock is owned by institutional investors.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.